kynurenic acid has been researched along with Parkinson Disease in 12 studies
Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.
kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Boosting KYNA levels, through interference with the KP enzymes or through application of prodrugs/analogs with high bioavailability and potency, is a promising clinical approach." | 2.82 | Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword? ( Ostapiuk, A; Urbanska, EM, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (33.33) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Ostapiuk, A | 1 |
| Urbanska, EM | 1 |
| Fathi, M | 1 |
| Vakili, K | 1 |
| Yaghoobpoor, S | 1 |
| Tavasol, A | 1 |
| Jazi, K | 1 |
| Hajibeygi, R | 1 |
| Shool, S | 1 |
| Sodeifian, F | 1 |
| Klegeris, A | 1 |
| McElhinney, A | 1 |
| Tavirani, MR | 1 |
| Sayehmiri, F | 1 |
| Rákóczi, K | 1 |
| Klivényi, P | 2 |
| Vécsei, L | 2 |
| Tan, L | 2 |
| Yu, JT | 1 |
| Hartai, Z | 1 |
| Janaky, T | 1 |
| Penke, B | 1 |
| Dux, L | 1 |
| Bezard, E | 2 |
| Boraud, T | 2 |
| Bioulac, B | 2 |
| Gross, CE | 2 |
| Ossowska, K | 1 |
| Lorenc-Koci, E | 1 |
| Konieczny, J | 1 |
| Wolfarth, S | 1 |
| Ravikumar, A | 1 |
| Deepadevi, KV | 1 |
| Arun, P | 1 |
| Manojkumar, V | 1 |
| Kurup, PA | 1 |
| Stone, TW | 1 |
| Wu, HQ | 1 |
| Rassoulpour, A | 1 |
| Schwarcz, R | 1 |
| Beal, MF | 1 |
| Matson, WR | 1 |
| Storey, E | 1 |
| Milbury, P | 1 |
| Ryan, EA | 1 |
| Ogawa, T | 1 |
| Bird, ED | 1 |
5 reviews available for kynurenic acid and Parkinson Disease
| Article | Year |
|---|---|
Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Topics: Alzheimer Disease; Animals; Brain; Excitatory Amino Acid Antagonists; Humans; Huntington Disease; Ky | 2022 |
Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.
Topics: 3-Hydroxyanthranilic Acid; Adenosine; Alzheimer Disease; Humans; Huntington Disease; Hydroxyindoleac | 2022 |
[Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings].
Topics: Animals; Creatine; Dopamine Agonists; Glatiramer Acetate; Humans; Indans; Kynurenic Acid; Micronutri | 2009 |
The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Topics: Aging; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Enzyme Inhibitors; Humans; Hunting | 2012 |
Kynurenic acid antagonists and kynurenine pathway inhibitors.
Topics: Brain Ischemia; Epilepsy; Excitatory Amino Acid Antagonists; Humans; Kynurenic Acid; Kynurenine; Neu | 2001 |
7 other studies available for kynurenic acid and Parkinson Disease
| Article | Year |
|---|---|
Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease.
Topics: Adaptation, Physiological; Aged; Brain; Erythrocytes; Female; Humans; Kynurenic Acid; Kynurenine; Ma | 2005 |
Presymptomatic revelation of experimental parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Kyn | 1997 |
Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental parkinsonism.
Topics: Animals; Disease Models, Animal; Glutamic Acid; Kynurenic Acid; Macaca; Parkinson Disease; Substanti | 1997 |
The role of striatal glutamate receptors in models of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dizocilpine Maleate; Electromyography; Excitatory | 1998 |
Tryptophan and tyrosine catabolic pattern in neuropsychiatric disorders.
Topics: Adult; Biogenic Monoamines; Brain Diseases; Brain Neoplasms; Digoxin; Epilepsy, Generalized; Erythro | 2000 |
Effect of systemic L-DOPA administration on extracellular kynurenate levels in the rat striatum.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Astrocytes; Dopamine; Dose-Response Relationship, | 2002 |
Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex.
Topics: Aged; Alzheimer Disease; Cerebral Cortex; Energy Metabolism; Free Radicals; Humans; Huntington Disea | 1992 |